Sterling Investment Advisors Ltd. increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 30.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,400 shares of the biotechnology company’s stock after buying an additional 1,250 shares during the quarter. Sterling Investment Advisors Ltd.’s holdings in United Therapeutics were worth $799,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of United Therapeutics by 0.7% in the second quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock valued at $494,291,000 after buying an additional 25,047 shares in the last quarter. State Street Corp grew its stake in shares of United Therapeutics by 0.9% in the second quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock valued at $261,345,000 after buying an additional 17,179 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of United Therapeutics by 2.4% in the fourth quarter. Acadian Asset Management LLC now owns 1,121,068 shares of the biotechnology company’s stock valued at $165,861,000 after buying an additional 26,122 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its stake in shares of United Therapeutics by 30.3% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 970,846 shares of the biotechnology company’s stock valued at $113,773,000 after buying an additional 225,953 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of United Therapeutics by 9.8% in the third quarter. Dimensional Fund Advisors LP now owns 798,093 shares of the biotechnology company’s stock valued at $93,531,000 after buying an additional 71,333 shares in the last quarter.

Shares of United Therapeutics Co. (NASDAQ:UTHR) opened at $136.97 on Monday. United Therapeutics Co. has a 12 month low of $112.01 and a 12 month high of $169.89. The firm has a market capitalization of $5,918.62, a P/E ratio of 12.08 and a beta of 1.41.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,260 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $121.46, for a total transaction of $153,039.60. Following the completion of the sale, the chief executive officer now owns 1,400 shares in the company, valued at approximately $170,044. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Christopher Causey sold 580 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $122.00, for a total value of $70,760.00. Following the sale, the director now owns 2,135 shares of the company’s stock, valued at approximately $260,470. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,245 shares of company stock valued at $1,622,581. 7.80% of the stock is owned by insiders.

A number of equities research analysts have recently issued reports on UTHR shares. ValuEngine upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research upgraded United Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 9th. HC Wainwright reiterated a “hold” rating and issued a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Oppenheimer increased their target price on United Therapeutics to $180.00 and gave the company an “outperform” rating in a research note on Friday, January 5th. Finally, Cowen reiterated a “hold” rating and issued a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $140.27.

TRADEMARK VIOLATION WARNING: “Sterling Investment Advisors Ltd. Buys 1,250 Shares of United Therapeutics Co. (UTHR)” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/01/29/sterling-investment-advisors-ltd-buys-1250-shares-of-united-therapeutics-co-uthr.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.